Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefazolin Sodium

FDA-approved product (injectable, injection), marketed as Ancef, Ancef In Dextrose 5% In Plastic Container, Ancef In Plastic Container and 5 more.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cefazolin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Endocarditis
  • Infection
  • Prostatitis
  • Sepsis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
First-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DB04

Repurposing investigation

Cefazolin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA78.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli88.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • K. pneumoniae90.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis45.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 2 of 4 lab records
Open Cefazolin Sodium in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefazolin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery

    NCT01805856 · start 2010-11

    Registered record
    Registry ID
    NCT01805856
    Conditions
    Thyroid Disease; Parathyroid Disease
    Interventions
    PIPC piperacillin sodium; CEZ, cefazolin sodium
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-11
    Completion
    2012-05
    Enrolment
    2,164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Disease; Parathyroid Disease
    InterventionPIPC piperacillin sodium; CEZ, cefazolin sodium
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Prophylactic Antibiotics on Intra-Operative Culture Results

    NCT01174212 · start 2010-07

    Registered record
    Registry ID
    NCT01174212
    Conditions
    Infection; Arthroplasty
    Interventions
    Prophylactic Antibiotics; Control Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-07
    Completion
    2012-07
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Arthroplasty
    InterventionProphylactic Antibiotics; Control Antibiotics
    PhasePhase 4
    Registry statusCompleted

  • Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

    NCT00634166 · start 2007-09

    Registered record
    Registry ID
    NCT00634166
    Conditions
    Burns
    Interventions
    Sulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-09
    Completion
    2014-04
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns
    InterventionSulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
    PhasePhase 4
    Registry statusTerminated

  • Prophylactic Antibiotic Use in Hernioplasty

    NCT00636831 · start 2007-07

    Registered record
    Registry ID
    NCT00636831
    Conditions
    Inguinal Hernia
    Interventions
    Antibiotic: cefazolin Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2012-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInguinal Hernia
    InterventionAntibiotic: cefazolin Sodium
    PhasePhase 3
    Registry statusCompleted

  • Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia

    NCT07186894 · start 2000-01-01

    Registered record
    Registry ID
    NCT07186894
    Conditions
    Bacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    Interventions
    Antistaphylococcal penicillins; Cefazolin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2000-01-01
    Completion
    2026-09-01
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    InterventionAntistaphylococcal penicillins; Cefazolin
    PhaseNot recorded
    Registry statusActive not recruiting